Susmed

Susmed EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Susmed (4263.T) as of Oct 28, 2026 is -330.16 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -299.48 M JPY — a change of 10.24% (lower).

EBITDA

-330.16 MJPY

YoY

10.24%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Susmed is 2026 -330.16 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Susmed was 2025 -299.48 M JPY. It decreases by 10.24% lower compared to the previous year.

The Susmed EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-160.73 M JPY
Jan 1, 2021
-333.42 M JPY
Jan 1, 2022
-233.16 M JPY
Jan 1, 2023
-49.54 M JPY
Jan 1, 2024
-364.98 M JPY
Jan 1, 2025
-299.48 M JPY
Jan 1, 2026
-330.16 M JPY
The Susmed EBITDA history
YEAREBITDAYoY
-330.16 MJPY+10.24%
-299.48 MJPY-17.95%
-364.98 MJPY+636.75%
-49.54 MJPY-78.75%
-233.16 MJPY-30.07%
-333.42 MJPY+107.44%
-160.73 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Susmed is -330.16 M JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Susmed changed from -299.48 M JPY to -330.16 M JPY, representing a 10.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Susmed since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Susmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Susmed

All Key Metrics — Susmed